Impact of clinical features of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients on osimertinib efficacy

類似資料

• Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer
  著者:: Gregorc, Vanesa, 等
  出版事項: (2018)
• Combined exosomal RNA and circulating tumor DNA for epidermal growth factor mutation detection in non-small cell lung cancer
  著者:: Lazzari, Chiara, 等
  出版事項: (2018)
• Mechanisms of resistance to osimertinib
  著者:: Lazzari, Chiara, 等
  出版事項: (2020)
• Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer
  著者:: Lazzari, Chiara, 等
  出版事項: (2018)
• Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
  著者:: Bracht, Jillian Wilhelmina Paulina, 等
  出版事項: (2019)